For citations:
Zyryanov S.K., Dyakov I.N. Cost-effectiveness analysis of acalabrutinib in treatment of patients with relapsed/refractory form of mantle cell lymphoma who previously received at least one line of therapy. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2024;17(2):129-136. (In Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2024.259
Views PDF (Rus): 244
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 